The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
|Articles|February 12, 2023
South Beach Symposium Recap: Day 4
Author(s)Kaitlyn Bader, Editor
Catch up on coverage from the final day of South Beach Symposium.
Advertisement
Updates on Biologics and Atopic Dermatitis With Andrew Alexis, MD
Alexis shares take-home points from his popular sessions at South Beach Symposium.
Atopic Dermatitis Considerations With Peter Lio, MD
Lio shares key highlights of his atopic dermatitis sessions at South Beach Symposium.
Analyzing the Gut-Skin-Brain Axis
Doris Day, MD, thoroughly discussed the up-and-coming topic of the gut-skin-brain axis related to healthy skin at SBS 2023.
Tirbanibulin Improves Skin in Patients with Actinic Keratosis
A poster presentation from SBS 2023 reviewed the clinician satisfaction of tirbanibulin for the treatment of actinic keratosis.
Visit our
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
FDA Revises TB Evaluation Guidance for SKYRIZI
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
5